GLP-1, GIP, and Triple-Agonist Peptides (Retatrutide)

Human clinical research demonstrates that incretin-based peptide therapies — including GLP-1 receptor agonists, dual GLP-1/GIP agonists, and triple-agonist peptides such as retatrutide — produce significant improvements in inflammation and metabolic function.

Inflammation

• Systematic reviews show GLP-1 receptor agonists reduce inflammatory biomarkers, including C-reactive protein (CRP) and pro-inflammatory cytokines (IL-6, TNF-α).

• Dual incretin therapies (GLP-1/GIP) demonstrate reductions in systemic inflammation alongside weight and metabolic improvements across SURMOUNT trial analyses.

• Emerging retatrutide research indicates substantial decreases in inflammatory markers, likely mediated through weight reduction, improved insulin sensitivity, and adipose tissue signaling changes.

Overall finding: Incretin-based peptides consistently show anti-inflammatory effects in human metabolic disease populations.

Metabolic Restoration

Large randomized clinical trials demonstrate these peptide therapies:

• Improve insulin sensitivity and glycemic control

• Produce significant weight reduction and fat mass loss

• Improve lipid metabolism and cardiometabolic risk markers

• Enhance metabolic flexibility and energy regulation

Dual and triple agonists (GLP-1/GIP and GLP-1/GIP/glucagon) show greater metabolic effects than single-pathway therapies, reflecting multi-hormone signaling.

Retatrutide trials report some of the largest weight-loss outcomes observed in peptide-based metabolic therapy research.

Mechanistic Evidence

Research shows incretin-based peptides influence:

• Appetite regulation pathways (central nervous system)

• Insulin signaling and glucose transport

• Adipose tissue inflammation and cytokine signaling

• Energy expenditure and mitochondrial activity

• Cardiometabolic inflammatory pathways

Triple-agonist peptides (retatrutide) additionally influence energy expenditure and glucagon signaling, contributing to enhanced metabolic restoration.

Other Peptides

MOTS-c (mitochondria-derived peptide)

What evidence supports (mostly preclinical + emerging human association data):

• Mechanistic work links MOTS-c to AMPK activation and pathways involved in insulin sensitivity and glucose metabolism.

• Reviews discuss MOTS-c as a regulator of metabolic homeostasis and stress response in the context of diabetes/metabolic disease.

• Human papers include observational findings (e.g., associations with obesity/metabolic status), but this is not the same as large interventional trials proving clinical benefit.

BPC-157

What evidence supports (mostly animal/in-vitro; very limited human data):

• A 2025 narrative review describes BPC-157’s potential to modulate inflammation, angiogenesis, nitric oxide signaling, and tissue repair, but underscores the overall evidence limitations.

• Orthopedic-focused review notes anti-inflammatory/healing signals in models and emphasizes lack of robust human safety/efficacy data.

Thymosin β4 / TB-4 (and TB-500 as a fragment used in wellness circles)

• Research in immune/inflammation contexts describes pro-resolving/inflammation-modulating mechanisms for thymosin β4 in disease models.

• Recent academic reviews keep exploring thymosin β4 biology and therapeutic roles in multiple models.

Bottom line: These peptides are biologically interesting, but for most of them, large, high-quality human trials demonstrating decreased systemic inflammation + improved metabolic outcomes are still lacking compared with GLP-1/GIP medications.

GHK-Cu (Copper Peptide)

• Skin remodeling / collagen: In human topical use over 12 weeks, GHK-Cu was reported to improve collagen measures and skin appearance outcomes in comparative work summarized in a major review.

• Anti-inflammatory signaling (preclinical + mechanistic): Reviews describe antioxidant/anti-inflammatory activity across in-vitro and in-vivo models, supporting biologic plausibility for inflammation modulation.

• Gut/inflammation models (preclinical): Recent animal research reports reduced inflammatory activity and improved barrier/tight-junction signals in colitis models.

“KLOW” Stacks (Stack/Blend Protocols)

• • KPV (Lys-Pro-Val): Demonstrated anti-inflammatory effects in murine colitis models and is studied for intestinal anti-inflammatory mechanisms.

Sermorelin (GHRH 1-29 analog) and GHRH-Analog Evidence

• Mechanism: Sermorelin/GHRH analogs stimulate the pituitary to increase endogenous GH and downstream IGF-1 (physiologic axis support vs direct GH administration).

• Clinical trial data (GHRH analogs in older adults): A randomized, placebo-controlled trial of a GHRH analog in adults reported endocrine/metabolic changes over months of administration.

• Cognition/brain outcomes (GHRH 1-29 NH₂): Randomized clinical trial work in older adults reported improvements on certain cognitive measures after months of GHRH (1-29 NH₂) treatment.